Obstetrics and Gynecology International

Obstetrics and Gynecology International / 2012 / Article
Special Issue


View this Special Issue

Review Article | Open Access

Volume 2012 |Article ID 531042 | 6 pages | https://doi.org/10.1155/2012/531042

Sperm DNA Integrity Assessment: A New Tool in Diagnosis and Treatment of Fertility

Academic Editor: Sanjeev Sharma
Received30 Jul 2011
Accepted23 Oct 2011
Published01 Dec 2011


Infertility affects 15% of all couples. Although male infertility factors with reduced semen quality are contributing to about half of all involuntary childlessness, the value of standard semen parameters in prediction of fertility in vivo and choice of proper method for assisted reproduction is limited. In the search for better markers of male fertility, during the last 10 years, assessment of sperm DNA integrity has emerged as a strong new biomarker of semen quality that may have the potential to discriminate between infertile and fertile men. Sperm DNA Fragmentation Index (DFI) as assessed by the flow cytometric Sperm Chromatin Structure Assay (SCSA) can be used for evaluation of sperm chromatin integrity. The biological background for abnormal DFI is not completely known, but clinical data show that DFI above 30% is associated with very low chance for achieving pregnancy in natural way or by insemination, but not in vitro. Already when the DFI is above 20%, the chance of natural pregnancy may be reduced, despite other sperm parameters being normal. Thus this method may explain a significant proportion of cases of unexplained infertility and can be beneficial in counselling involuntary childless couples need of in vitro fertilisation.

1. Introduction

In western countries up to one-forth of couples in reproductive age are seeking medical help for involuntary childlessness [1]. Despite the significant developments in the area of fertility seen during the last decades about one-third of these couples will be undiagnosed without any explanation to their problems.

Although, the traditional semen parameters concentration, motility, and morphology are a golden standard in diagnosing of male infertility it has become apparent that none of these parameters recommended by the Word Health Organization (WHO) [2] are sufficient for the prediction of male fertility capacity. As the WHO parameters only address few aspects of sperm quality and function the discriminative power in relation to fertility is quite low [3, 4].

As a result, there has for long been searched for better markers of male fertility.

During the last decades the use of assisted reproductive techniques (ARTs) has increased substantially [1, 5]. In particular intracytoplasmic sperm injection (ICSI) is used to an increasing degree. While in the beginning of the era of ICSI the indication for treatment was severe male factor infertility, now also couples with normal sperm quality request are treated with ICSI. However, IVF and ICSI are symptomatic treatments where only 25–30% of the treatments result in a delivery [6]. One explanation to this limited success can be the lack of markers to find the underlying causes to subfertility and also a lack of methods to identify the type of ART treatment providing the most optimal chances of pregnancy in a given couple.

During the last decade the search for better predictors of male fertility has resulted in an increased focus on the sperm DNA integrity [7, 8]. Now number of sperm chromatin integrity assays is available. Among the most frequently used are the Comet assay (single cell gel electrophoresis) [9], the TUNEL (terminal deoxynucleotidyl transferase-mediated dUDP nick end labelling) assay [10], the sperm chromatin dispersion (SCD) [11, 12], and the sperm chromatin structure assay (SCSA) [13, 14]. The clinical value of these different tests varies; however, SCSA, first described by Evenson et al. [13] is shown to be an independent marker of fertility in vivo and may also help in selection of the most effective ART treatment in each individual couple [15]. This paper will discuss how sperm DNA integrity assessment by help of SCSA can be used as a tool in diagnosis and treatment of infertility.

2. Aetiology and Diagnosis of Infertility

Involuntary childlessness, infertility can be a result of female, male as well as combined factors. It is a complex condition where often a mix of factors plays a role. In 20% of cases, the predominant cause is solely male related and, in another 30%, anomalies in both partners contribute to the childlessness [2]. Traditionally genital infections, endocrine disturbances, and immunological factors have been regarded as the most common causes of male subfertility. However, now more often genetic/molecular causes are identified as contributing factors [16], as,for instance, chromatin defects assessed as breaks in sperm DNA [7, 14, 1719]. However, it is a fact that in 60–75% of the male-caused cases the aetiology of reduced semen quality remains unexplained and is therefore diagnosed as idiopathic infertility [2].

The golden standard in the diagnosis of male infertility or subfertility is an analysis of sperm concentration, motility, and morphology where WHO has set threshold levels for normality in regard to fertility [2]. However, this WHO sperm analysis is mainly performed by light microscopy of 100–200 spermatozoa and thus the analysis is biased because of a high level of subjectivity resulting in a high grade of intra- and interlaboratory variation [20, 21]. As a consequence a low predictive value of the WHO analysis is reported. Another drawback with the WHO parameters is that they only address few aspects of sperm quality and function. During the last decades, several other sperm function tests have been suggested to be used, including vital staining, hemizona assay, biochemical analysis of semen, antisperm antibody test, hypoosmotic swelling test, sperm penetration assay, reactive oxygen species (ROS) tests, and computer-assisted sperm analysis (CASA) [18]. However, as none of them have provided stable threshold values few are actually used in clinical routine [22].

Now an increasing amount of data demonstrate an association between sperm DNA damage and fertility [7, 14, 17, 19, 2326]. It has been proposed that sperm DNA integrity could be a fertility predictor to be used as a supplement to the traditional sperm parameters [14, 15, 27].

3. Causes to Sperm DNA Damage

Spermatogenesis is a complex process [28] where damage of sperm chromatin structure can occur at any step (reviewed in [7]). DNA damage in sperm can be due to unrepaired DNA breaks during the spermatogenetic chromatin remodeling and packaging or abortive apoptosis during spermatogenesis. Among other suggested causes are the effect of endogenous endonucleases and caspases, exposure to a variety of genotoxic agents because of therapeutic reasons or because of occupational or environmental exposures, and finally, the action of oxidative sperm DNA damage [19]. Most likely often these factors are interrelating. Problems in the crossing-over process during spermatogenesis or deficiencies in the protamination process will likely make sperm more vulnerable to oxidative stress at a later occasion.

3.1. Remodeling and Packaging Problems

Meiotic crossing-over during spermatogenesis is associated with the programmed introduction of DNA double-strand breaks, expected to be ligated until the end of meiosis I [29]. Stage-specific introduction of transient DNA strand breaks during spermiogenesis has been described [30, 31]. DNA breaks are needed for transient relief of torsional stress, favouring the histone replacement with protamines during the final maturation form round to elongated spermatozoa [31, 32]. However, if and only if these physiological, normal temporary breaks are not repaired, DNA fragmentation in ejaculated spermatozoa or genetic mutations may occur [33].

3.2. Abortive Apoptosis

Another suggested aetiology of DNA damage is that breaks can arise through abortive apoptosis. Apoptosis of testicular germ cells occurs normally throughout life, controlling overproliferation [34]; however, it has been suggested an early apoptotic pathway, initiated in spermatogonia and spermatocytes, mediated by the Fas protein [35]. Sertoli cells in the testis express Fas ligand, which by binding to Fas leads to cell death through apoptosis [35].

3.3. Oxidative Stress

Oxidative stress (OS) caused by an imbalance between the antioxidant ability in seminal plasma and the production of reactive oxygen species (ROS) leading to the formation of oxidative products such as 8OHdG is the mechanism that probably most often lies behind sperm DNA defects. The sperm cell membrane is easily attacked by ROS with further detrimental effects on nuclear membranes as well as on sperm DNA [33]. Moreover, sperm lack antioxidants and DNA repair systems [36] and therefore protection of the offspring from the negative effects of male-induced DNA strand breaks is always dependant on the repair capacity of the oocyte and the early embryo. The main sources of ROS in semen are leukocytes and abnormal/dead spermatozoa in the semen [19, 37, 38]; however, increased scrotal temperature due to illness with fever [3941], varicocele [42], increased age [4347], and smoking [4854] are also reported as sources.

4. Sperm DNA Integrity Assessment

Currently, four major tests of sperm DNA fragmentation are most frequently used, including the Comet assay (single cell gel electrophoresis) [9], the TUNEL (terminal deoxynucleotidyl transferase-mediated dUDP nick end labelling) assay [10], the sperm chromatin dispersion (SCD) test [11, 12], and the sperm chromatin structure assay (SCSA) [13, 14]. They all label single- or double-stranded DNA breaks; however unfortunately, most of the available techniques for detection of sperm DNA damage provide limited information on the nature of the DNA lesions detected and none of them enables us to depict the exact aetiology and pathogenesis of impairment of sperm DNA.

Comet assay is a fluorescence microscopic test, and TUNEL assay can be applied in both bright field/fluorescence microscopy and by flow cytometry. In Comet assay sperm cells are mixed with melted agarose and then placed on a glass slide. The cells are lysed and then subjected to horizontal electrophoresis. DNA is visualized with the help of a DNA-specific fluorescent dye and DNA damage is quantified by measuring the displacement between the genetic material of the nucleus comet head and the resulting tail. In the TUNEL assay, terminal deoxynucleotidyl transferase (TdT) incorporates labelled (by and large fluorescent) nucleotides to 3′-OH at single- and double-strand DNA breaks to create a signal, which increases with the number of DNA breaks. The fluorescence intensity of each analyzed sperm is determined as a “positive” or “negative” for sperm on a microscope slide. In a flow cytometer the fraction of positive sperm is represented by the cells above a threshold channel value on a relative fluorescent intensity scale.

SCSA is a flowcytometric test where sperm DNA breaks are evaluated indirectly through the DNA denaturability. The assay measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ, followed by staining with the fluorescence dye acridine orange [13, 14, 55]. By using a flow cytometer 5.000–10.000 sperm can be analyzed within few seconds and thus provide a less subjective result compared to the WHO analysis where only 1–300 cells are analyzed. Through a specific SCSA-software (SCSA-Soft) a scatter plot is created, showing the ratio of green and red sperm. The percentage of red sperm is called DNA fragmentation index (DFI) [14]. The sperm with the most intensive green colour is called high DNA stainable (HDS) sperm. It is still unclear precisely which mechanisms and types of DNA damage are lying behind DFI and HDS; however, it is believed that whilst DFI is related to the percentage of sperm with DNA breaks or protamine defects HDS is thought to represent immature spermatozoa [14].

So far, the SCSA is the only sperm DNA integrity assessment method which has demonstrated clear and clinically useful cut-off levels for calculating male fertility potential [13, 15, 27, 55]. The SCSA is a standardized test performed according to a strict protocol [14]. Apart from being subject to a very limited intralaboratory variation [56], however, the SCSA analysis has shown to be very robust to variation between laboratories. In an external quality control based on >180 samples, a high ( ) correlation was found between the values obtained by our laboratory and those from a control laboratory. Furthermore, the absolute DFI values obtained at two different laboratories, using different equipment, did not on average differ by >1% [57].

The advantage of SCSA is the objectivity of the test as well as the high reproducibility when running after the standardised protocol. Moreover, the clear cut-off levels in relation to fertility are maybe the most obvious benefit compared to other sperm DNA integrity tests. A disadvantage is that an expensive flow cytometer is required to run the analysis. Moreover, the test irreversibly damages spermatozoa; after analysis they cannot be used for fertilisation purposes.

Studies have demonstrated that these four sperm DNA integrity tests, the SCSA, TUNEL, Comet, and SCD assays, generally correlate moderately with each other (a coefficient of correlation between 0.4 and 0.7), which indicates that the tests likely are expressing different aspects of sperm DNA damage.

5. SCSA and the Chance of Pregnancy

Two population-based studies, including 165 and 215 couples respectively, [13, 55], have demonstrated that DFI as measured with SCSA is an excellent predictor of subfecundity in the normal population. In the interval of DFI 0–20%, the chance of spontaneous pregnancy was constant. When DFI was above 20% the chance of obtaining a spontaneous pregnancy was decreased and close to zero when the DFI level passed 30–40%. Even though DFI was below 20%, only 13% of all cycles resulted in a pregnancy. Therefore, in a normal population, not selected because of infertility problems, SCSA is a valuable tool to identify men who are at risk of not giving rise to a pregnancy. The same information is not possible to get from the traditional WHO sperm parameters. Even among men with low sperm concentration, poor motility or morphology there will be men with a certain potential of fertility [3].

In a case-control study of 137 infertile and 127 fertile men the risk of being infertile was found to be increased when DFI as measured by SCSA was above 20% in men with normal standard semen parameters, an odds ratio (OR) of 5.1, (CI: 1.2–23), compared to fertile controls [27]. If one of the WHO parameters was abnormal, the OR for infertility was increased already at DFI above 10% (OR 16, CI: 4.2–60). A DFI above 20% was found in 40% of the men with otherwise normal standard parameters. DFI was also shown to be an independent predictor of spontaneous pregnancy. Erenpreiss and coworkers found that 20% of the men with otherwise normal WHO sperm parameters had an SCSA-DFI above 20% [58].

The association between sperm DNA damage and the traditional semen parameters is shown to be only weak to moderate [57, 59]. It is also shown that 25–40% of infertile men may have normal standard sperm characteristics according to WHO criteria, but a DFI above 20–30% [15, 27, 58].

ART includes all technologies that involve the handling of sperm outside the body, as in intrauterine insemination (IUI), or handling of oocytes, sperm, and embryos as in in vitro fertilization (IVF) and ICSI [60]. In IVF, the spermatozoas ability to penetrate the zona pellucida of the oocyte is utilized. In ICSI, however, one single spermatozoon is selected and injected directly into the cytoplasm of the oocyte. Despite these obvious differences most studies report results from the three types of treatments together. In studies reporting the three treatment types separately, the number of patients included and thus the statistical power have been relatively low. The first SCSA study to indicate an association between sperm DNA damage and reduced pregnancy chances was published by Saleh et al. [61] who performed a small study where 12 of 19 couples had a DFI value as measured by SCSA above 28% and no pregnancy was obtained. Also, Boe-Hansen and coworkers in a study on 48 IUI couples found only two couples with a DFI value above 30%, and neither here pregnancy was obtained [62]. Recently, in a study of 387 IUI cycles, we have shown that even in IUI SCSA-DFI can be used as an independent predictor of fertility [15]. Whilst the proportion of children born per cycle was 19.0% when the DFI value was below 30%, those with a DFI value above 30% only had a take-home-baby rate of 1.5%. In this group the OR for delivery in relation to DFI <30% was 0.07 (95% confidence interval (CI): 0.01–0.48). In the same study, 388 IVF and 223 ICSI cycles were included but it was not possible to find any threshold value for DFI that could predict the result of the treatments. However, surprisingly when DFI exceeded 30%, the result of ICSI was significantly better than IVF (OR for delivery was 2.17 (CI 1.04–4.51)). These data are in agreement with other previous smaller reports using TUNEL or COMET assays, showing that sperm DNA damage is more predictive in IVF and much less so in ICSI [63, 64].

Although fertilization and embryo development may be independent of sperm DNA integrity, it has been suggested that the postfertilization development of the pre-embryo can be impaired by such incomplete or aberrant sperm DNA repair by the oocyte leading to early miscarriages (reviewed in [65]) or in the worst cases diseases in the offspring [8, 66, 67]. In our study of about 1000 couples no relationship was seen between sperm DNA fragmentation and unexplained pregnancy loss [15].

The other SCSA parameter, HDS, was neither in ours nor in other studies found to be of predictive value of pregnancy.

6. Clinical Recommendations

SCSA represents a valuable tool in diagnosis and treatment of infertility. The usefulness of the method is first of all relating to in vivo fertility (spontaneous pregnancy and IUI) and in particular in the many couples diagnosed with unexplained infertility. In 20% of men presenting with otherwise normal semen parameters, the SCSA-DFI is above 30% and in these couples the chance of pregnancy is close to zero [15] that is why they should be directly referred to IVF/ICSI. Through such a strategy change one-fifth of all couples normally referred to IUI can avoid the huge burden an unsuccessful ART treatment represents.

In as many as 40% of all unexplained infertile couples the explanation may be related to a high DFI. In a couple having a DFI between 20 and 30% time to pregnancy will be longer than in a couple with a DFI level below 20%. This is important information that should be utilized in counselling the couple. Combining SCSA-DFI with assessment of traditional WHO sperm parameters is shown to give a higher precision in the prediction of fertility. If one of the WHO sperm parameters is that abnormal fertility becomes reduced already when DFI exceeds the level of 10%, whereas the DFI level is above 30%, couple should be revised directly to IVF/ICSI. However, the status is that still very few clinics have implemented sperm chromatin integrity testing and therefore most couples seeking help for infertility problems are not aware of their actual potential sperm DNA defects. One reason is the necessity of expensive equipment as, for instance, a flow cytometer as well as time, cost, and expertise to perform the analysis. On the other hand, sperm samples can be shipped to and analyzed on a centralized SCSA laboratory.

Sperm DNA breaks are mainly thought to be a result of oxidative stress. Some reports demonstrating a positive effect of antioxidant therapy in men with a high DFI have been published; however, the study populations have been small and data conflicting [45, 6873]. In the future SCSA may also have the potential to give indications for a causal treatment of disturbances of male fertility.

Development of new improved tests depicting the cause of sperm DNA damage should be the next step in using sperm DNA integrity testing as a tool in diagnosis and treatment of infertility.


  1. D. B. Dunson, D. D. Baird, and B. Colombo, “Increased infertility with age in men and women,” Obstetrics and Gynecology, vol. 103, no. 1, pp. 51–56, 2004. View at: Publisher Site | Google Scholar
  2. WHO, WHO Laboratory Manual for the Examination and Processing of Human Semen, WHO Press, 2010.
  3. D. S. Guzick, J. W. Overstreet, P. Factor-Litvak et al., “Sperm morphology, motility, and concentration in fertile and infertile men,” New England Journal of Medicine, vol. 345, no. 19, pp. 1388–1393, 2001. View at: Publisher Site | Google Scholar
  4. J. P. E. Bonde, E. Ernst, T. K. Jensen et al., “Relation between semen quality and fertility: a population-based study of 430 first-pregnancy planners,” The Lancet, vol. 352, no. 9135, pp. 1172–1177, 1998. View at: Publisher Site | Google Scholar
  5. A. N. Andersen, V. Goossens, A. P. Ferraretti et al., “Assisted reproductive technology in Europe, 2004: results generated from European registers by ESHRE,” Human Reproduction, vol. 23, no. 4, pp. 756–771, 2008. View at: Publisher Site | Google Scholar
  6. A. N. Andersen, L. Gianaroli, R. Felberbaum et al., “Assisted reproductive technology in Europe, 2001. Results generated from European registers by ESHRE,” Human Reproduction, vol. 20, no. 5, pp. 1158–1176, 2005. View at: Publisher Site | Google Scholar
  7. J. Erenpreiss, M. Spano, J. Erenpreisa, M. Bungum, and A. Giwercman, “Sperm chromatin structure and male fertility: Biological and clinical aspects,” Asian Journal of Andrology, vol. 8, no. 1, pp. 11–29, 2006. View at: Publisher Site | Google Scholar
  8. A. Agarwal and T. M. Said, “Role of sperm chromatin abnormalities and DNA damage in male infertility,” Human Reproduction Update, vol. 9, no. 4, pp. 331–345, 2003. View at: Publisher Site | Google Scholar
  9. I. D. Morris, S. Ilott, L. Dixon, and D. R. Brison, “The spectrum of DNA damage in human sperm assessed by single cell gel electrophoresis (Comet assay) and its relationship to fertilization and embryo development,” Human Reproduction, vol. 17, no. 4, pp. 990–998, 2002. View at: Google Scholar
  10. W. Gorczyca, J. Gong, and Z. Darzynkiewicz, “Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays,” Cancer Research, vol. 53, no. 8, pp. 1945–1951, 1993. View at: Google Scholar
  11. J. L. Fernández, L. Muriel, M. T. Rivero, V. Goyanes, R. Vazquez, and J. G. Alvarez, “The sperm chromatin dispersion test: a simple method for the determination of sperm DNA fragmentation,” Journal of Andrology, vol. 24, no. 1, pp. 59–66, 2003. View at: Google Scholar
  12. J. L. Fernández, L. Muriel, V. Goyanes et al., “Simple determination of human sperm DNA fragmentation with an improved sperm chromatin dispersion test,” Fertility and Sterility, vol. 84, no. 4, pp. 833–842, 2005. View at: Publisher Site | Google Scholar
  13. D. P. Evenson, Z. Darzynkiewicz, and M. R. Melamed, “Relation of mammalian sperm chromatin heterogeneity to fertility,” Science, vol. 210, no. 4474, pp. 1131–1133, 1980. View at: Google Scholar
  14. D. P. Evenson, K. L. Larson, and L. K. Jost, “Sperm chromatin structure assay: Its clinical use for detecting sperm DNA fragmentation in male infertility and comparisons with other techniques,” Journal of Andrology, vol. 23, no. 1, pp. 25–43, 2002. View at: Google Scholar
  15. M. Bungum, P. Humaidan, A. Axmon et al., “Sperm DNA integrity assessment in prediction of assisted reproduction technology outcome,” Human Reproduction, vol. 22, no. 1, pp. 174–179, 2007. View at: Publisher Site | Google Scholar
  16. A. Ferlin, F. Raicu, V. Gatta, D. Zuccarello, G. Palka, and C. Foresta, “Male infertility: Role of genetic background,” Reproductive BioMedicine Online, vol. 14, no. 6, pp. 734–745, 2007. View at: Google Scholar
  17. M. Spano, E. Seli, D. Bizzaro, G. C. Manicardi, and D. Sakkas, “The significance of sperm nuclear DNA strand breaks on reproductive outcome,” Current Opinion in Obstetrics and Gynecology, vol. 17, no. 3, pp. 255–260, 2005. View at: Google Scholar
  18. R. J. Aitken, G. N. De Iuliis, and R. I. Mclachlan, “Biological and clinical significance of DNA damage in the male germ line,” International Journal of Andrology, vol. 32, no. 1, pp. 46–56, 2009. View at: Publisher Site | Google Scholar
  19. D. Sakkas and J. G. Alvarez, “Sperm DNA fragmentation: mechanisms of origin, impact on reproductive outcome, and analysis,” Fertility and Sterility, vol. 93, no. 4, pp. 1027–1036, 2010. View at: Publisher Site | Google Scholar
  20. T. G. Cooper, J. Neuwinger, S. Bahrs, and E. Nieschlag, “Internal quality control of semen analysis,” Fertility and Sterility, vol. 58, no. 1, pp. 172–178, 1992. View at: Google Scholar
  21. J. Neuwinger, H. M. Behre, and E. Nieschlag, “External quality control in the andrology laboratory: an experimental multicenter trial,” Fertility and Sterility, vol. 54, no. 2, pp. 308–314, 1990. View at: Google Scholar
  22. C. H. Muller, “Andrology lab corner: rationale, interpretation, validation, and uses of sperm function tests,” Journal of Andrology, vol. 21, no. 1, pp. 10–30, 2000. View at: Google Scholar
  23. D. Evenson and R. Wixon, “Meta-analysis of sperm DNA fragmentation using the sperm chromatin structure assay,” Reproductive BioMedicine Online, vol. 12, no. 4, article 2037, pp. 466–472, 2006. View at: Google Scholar
  24. N. Tarozzi, D. Bizzaro, C. Flamigni, and A. Borini, “Clinical relevance of sperm DNA damage in assisted reproduction,” Reproductive BioMedicine Online, vol. 14, no. 6, pp. 746–757, 2007. View at: Google Scholar
  25. A. Zini and J. Libman, “Sperm DNA damage: Importance in the era of assisted reproduction,” Current Opinion in Urology, vol. 16, no. 6, pp. 428–434, 2006. View at: Publisher Site | Google Scholar
  26. A. Zini and M. Sigman, “Are tests of sperm DNA damage clinically useful? Pros and cons,” Journal of Andrology, vol. 30, no. 3, pp. 219–229, 2009. View at: Publisher Site | Google Scholar
  27. A. Giwercman, L. Lindstedt, M. Larsson et al., “Sperm chromatin structure assay as an independent predictor of fertility in vivo: a case-control study,” International Journal of Andrology, vol. 33, no. 1, pp. e221–e227, 2010. View at: Publisher Site | Google Scholar
  28. D. M. De Kretser, K. L. Loveland, A. Meinhardt, D. Simorangkir, and N. Wreford, “Spermatogenesis,” Human Reproduction, vol. 13, supplement 1, pp. 1–8, 1998. View at: Publisher Site | Google Scholar
  29. L. A. Bannister and J. C. Schimenti, “Homologous recombinational repair proteins in mouse meiosis,” Cytogenetic and Genome Research, vol. 107, no. 3-4, pp. 191–200, 2004. View at: Publisher Site | Google Scholar
  30. D. Sakkas, G. Manicardi, P. G. Bianchi, D. Bizzaro, and U. Bianchi, “Relationship between the presence of endogenous nicks and sperm chromatin packaging in maturing and fertilizing mouse spermatozoa,” Biology of Reproduction, vol. 52, no. 5, pp. 1149–1155, 1995. View at: Google Scholar
  31. L. Marcon and G. Boissonneault, “Transient DNA strand breaks during mouse and human spermiogenesis: new insights in stage specificity and link to chromatin remodeling,” Biology of Reproduction, vol. 70, no. 4, pp. 910–918, 2004. View at: Publisher Site | Google Scholar
  32. S. M. G. McPhersson and F. J. Longo, “Nicking of rat spermatid and spermatozoa DNA: possible involvement of DNA topoisomerase II,” Developmental Biology, vol. 158, no. 1, pp. 122–130, 1993. View at: Publisher Site | Google Scholar
  33. R. J. Aitken and C. Krausz, “Oxidative stress, DNA damage and the Y chromosome,” Reproduction, vol. 122, no. 4, pp. 497–506, 2001. View at: Google Scholar
  34. H. Billig, I. Furuta, C. Rivier, J. Tapanainen, M. Parvinen, and A. J. W. Hsueh, “Apoptosis in testis germ cells: developmental changes in gonadotropin dependence and localization to selective tubule stages,” Endocrinology, vol. 136, no. 1, pp. 5–12, 1995. View at: Google Scholar
  35. T. Suda, T. Takahashi, P. Golstein, and S. Nagata, “Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family,” Cell, vol. 75, no. 6, pp. 1169–1178, 1993. View at: Publisher Site | Google Scholar
  36. R. J. Aitken, M. A. Baker, and D. Sawyer, “Oxidative stress in the male germ line and its role in the aetiology of male infertility and genetic disease,” Reproductive BioMedicine Online, vol. 7, no. 1, pp. 65–70, 2003. View at: Google Scholar
  37. R. J. Aitken, D. Buckingham, K. West, F. C. Wu, K. Zikopoulos, and D. W. Richardson, “Differential contribution of leucocytes and spermatozoa to the generation of reactive oxygen species in the ejaculates of oligozoospermic patients and fertile donors,” Journal of Reproduction and Fertility, vol. 94, no. 2, pp. 451–462, 1992. View at: Google Scholar
  38. R. A. Saleh, A. Agarwal, E. Kandirali et al., “Leukocytospermia is associated with increased reactive oxygen species production by human spermatozoa,” Fertility and Sterility, vol. 78, no. 6, pp. 1215–1224, 2002. View at: Publisher Site | Google Scholar
  39. D. Evenson and L. Jost, “Sperm chromatin structure assay is useful for fertility assessment,” Methods in Cell Science, vol. 22, no. 2-3, pp. 169–189, 2000. View at: Publisher Site | Google Scholar
  40. D. P. Evenson, L. K. Jost, R. K. Baer, T. W. Turner, and S. M. Schrader, “Individuality of DNA denaturation patterns in human sperm as measured by the sperm chromatin structure assay,” Reproductive Toxicology, vol. 5, no. 2, pp. 115–125, 1991. View at: Google Scholar
  41. M. Sergerie, R. Mieusset, F. Croute, M. Daudin, and L. Bujan, “High risk of temporary alteration of semen parameters after recent acute febrile illness,” Fertility and Sterility, vol. 88, no. 4, pp. e1.970–e7.970, 2007. View at: Publisher Site | Google Scholar
  42. R. A. Saleh, A. Agarwal, R. K. Sharma, T. M. Said, S. C. Sikka, and A. J. Thomas, “Evaluation of nuclear DNA damage in spermatozoa from infertile men with varicocele,” Fertility and Sterility, vol. 80, no. 6, pp. 1431–1436, 2003. View at: Publisher Site | Google Scholar
  43. K. Plastira, R. Angelopoulou, D. Mantas et al., “The effects of age on the incidence of aneuploidy rates in spermatozoa of oligoasthenozoospermic patients and its relationship with ICSI outcome,” International Journal of Andrology, vol. 30, no. 2, pp. 65–72, 2007. View at: Publisher Site | Google Scholar
  44. S. I. Moskovtsev, J. Willis, and J. B. M. Mullen, “Age-related decline in sperm deoxyribonucleic acid integrity in patients evaluated for male infertility,” Fertility and Sterility, vol. 85, no. 2, pp. 496–499, 2006. View at: Publisher Site | Google Scholar
  45. E. W. Silver, B. Eskenazi, D. P. Evenson, G. Block, S. Young, and A. J. Wyrobek, “Effect of antioxidant intake on sperm chromatin stability in healthy nonsmoking men,” Journal of Andrology, vol. 26, no. 4, pp. 550–556, 2005. View at: Publisher Site | Google Scholar
  46. M. Spanò, A. H. Kolstad, S. B. Larsen et al., “The applicability of the flow cytometric sperm chromatin structure assay in epidemiological studies,” Human Reproduction, vol. 13, no. 9, pp. 2495–2505, 1998. View at: Publisher Site | Google Scholar
  47. N. P. Singh, C. H. Muller, and R. E. Berger, “Effects of age on DNA double-strand breaks and apoptosis in human sperm,” Fertility and Sterility, vol. 80, no. 6, pp. 1420–1430, 2003. View at: Publisher Site | Google Scholar
  48. C. G. Fraga, P. A. Motchnik, A. J. Wyrobek, D. M. Rempel, and B. N. Ames, “Smoking and low antioxidant levels increase oxidative damage to sperm DNA,” Mutation Research, vol. 351, no. 2, pp. 199–203, 1996. View at: Publisher Site | Google Scholar
  49. R. J. Potts, C. J. Newbury, G. Smith, L. J. Notarianni, and T. M. Jefferies, “Sperm chromatin damage associated with male smoking,” Mutation Research, vol. 423, no. 1-2, pp. 103–111, 1999. View at: Publisher Site | Google Scholar
  50. J. G. Sun, A. Jurisicova, and R. F. Casper, “Detection of deoxyribonucleic acid fragmentation in human sperm: correlation with fertilization in vitro,” Biology of Reproduction, vol. 56, no. 3, pp. 602–607, 1997. View at: Publisher Site | Google Scholar
  51. R. A. Saleh, A. Agarwal, D. R. Nelson et al., “Increased sperm nuclear DNA damage in normozoospermic infertile men: a prospective study,” Fertility and Sterility, vol. 78, no. 2, pp. 313–318, 2002. View at: Publisher Site | Google Scholar
  52. S. Sepaniak, T. Forges, H. Gerard, B. Foliguet, M. C. Bene, and P. Monnier-Barbarino, “The influence of cigarette smoking on human sperm quality and DNA fragmentation,” Toxicology, vol. 223, no. 1-2, pp. 54–60, 2006. View at: Publisher Site | Google Scholar
  53. W. A. Robbins, M. F. Vine, K. Young Truong, and R. B. Everson, “Use of fluorescence in situ hybridization (FISH) to assess effects of smoking, caffeine, and alcohol on aneuploidy load in sperm of healthy men,” Environmental and Molecular Mutagenesis, vol. 30, no. 2, pp. 175–183, 1997. View at: Publisher Site | Google Scholar
  54. J. Rubes, X. Lowe, D. Moore et al., “Smoking cigarettes is associated with increased sperm disomy in teenage men,” Fertility and Sterility, vol. 70, no. 4, pp. 715–723, 1998. View at: Publisher Site | Google Scholar
  55. M. Spanò, J. P. Bonde, H. I. Hjøllund, H. A. Kolstad, E. Cordelli, and G. Leter, “Sperm chromatin damage impairs human fertility. The Danish First Pregnancy Planner study team,” Fertility and Sterility, vol. 73, no. 1, pp. 43–50, 2000. View at: Publisher Site | Google Scholar
  56. A. Giwercman, M. Spano, J. Lähdetie, and J. P.E. Bonde, “Quality assurance of semen analysis in multicenter studies,” Scandinavian Journal of Work, vol. 25, supplement 1, pp. 23–25, 1999. View at: Google Scholar
  57. A. Giwercman, J. Richthoff, H. Hjøllund et al., “Correlation between sperm motility and sperm chromatin structure assay parameters,” Fertility and Sterility, vol. 80, no. 6, pp. 1404–1412, 2003. View at: Publisher Site | Google Scholar
  58. J. Erenpreiss, S. Elzanaty, and A. Giwercman, “Sperm DNA damage in men from infertile couples,” Asian Journal of Andrology, vol. 10, no. 5, pp. 786–790, 2008. View at: Publisher Site | Google Scholar
  59. M. Spanò, E. Cordelli, G. Leter, and F. Pacchierotti, “Diepoxybutane cytotoxicity on mouse germ cells is enhanced by in vivo glutathione depletion: a flow cytometric approach,” Mutation Research, vol. 397, no. 1, pp. 37–43, 1998. View at: Publisher Site | Google Scholar
  60. R. G. Edwards and Brody S. A., Principles and Practice of Assisted Human Reproduction, W.B Saunders, Philadelphia, Pa, USA, 1995.
  61. R. A. Saleh, A. Agarwal, E. A. Nada et al., “Negative effects of increased sperm DNA damage in relation to seminal oxidative stress in men with idiopathic and male factor infertility,” Fertility and Sterility, vol. 79, supplement 3, pp. 1597–1605, 2003. View at: Publisher Site | Google Scholar
  62. G. B. Boe-Hansen, J. Fedder, A. K. Ersbøll, and P. Christensen, “The sperm chromatin structure assay as a diagnostic tool in the human fertility clinic,” Human Reproduction, vol. 21, no. 6, pp. 1576–1582, 2006. View at: Publisher Site | Google Scholar
  63. M. E. Hammadeh, M. Stieber, G. Haidl, and W. Schmidt, “Association between sperm cell chromatin condensation, morphology based on strict criteria, and fertilization, cleavage and pregnancy rates in an IVF program,” Andrologia, vol. 30, no. 1, pp. 29–35, 1998. View at: Google Scholar
  64. E. Høst, S. Lindenberg, and S. Smidt-Jensen, “The role of DNA strand breaks in human spermatozoa used for IVF and ICSI,” Acta Obstetricia et Gynecologica Scandinavica, vol. 79, no. 7, pp. 559–563, 2000. View at: Publisher Site | Google Scholar
  65. A. Zini, J. M. Boman, E. Belzile, and A. Ciampi, “Sperm DNA damage is associated with an increased risk of pregnancy loss after IVF and ICSI: Systematic review and meta-analysis,” Human Reproduction, vol. 23, no. 12, pp. 2663–2668, 2008. View at: Publisher Site | Google Scholar
  66. C.-H. Liu, H.-M. Tsao, T.-C. Cheng et al., “DNA fragmentation, mitochondrial dysfunction and chromosomal aneuploidy in the spermatozoa of oligoasthenoteratozoospermic males,” Journal of Assisted Reproduction and Genetics, vol. 21, no. 4, pp. 119–126, 2004. View at: Publisher Site | Google Scholar
  67. R. J. Aitken and M. A. Baker, “Oxidative stress and male reproductive biology,” Reproduction, Fertility and Development, vol. 16, no. 5, pp. 581–588, 2004. View at: Publisher Site | Google Scholar
  68. S. E. Lewis, I. Agbaje, and J. Alvarez, “Sperm DNA tests as useful adjuncts to semen analysis,” Systems Biology in Reproductive Medicine, vol. 54, no. 3, pp. 111–125, 2008. View at: Google Scholar
  69. E. Greco, M. Iacobelli, L. Rienzi, F. Ubaldi, S. Ferrero, and J. Tesarik, “Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment,” Journal of Andrology, vol. 26, no. 3, pp. 349–353, 2005. View at: Publisher Site | Google Scholar
  70. E. Greco, S. Romano, M. Iacobelli et al., “ICSI in cases of sperm DNA damage: beneficial effect of oral antioxidant treatment,” Human Reproduction, vol. 20, no. 9, pp. 2590–2594, 2005. View at: Publisher Site | Google Scholar
  71. Y. J. R. Ménézo, A. Hazout, G. Panteix et al., “Antioxidants to reduce sperm DNA fragmentation: an unexpected adverse effect,” Reproductive BioMedicine Online, vol. 14, no. 4, pp. 418–421, 2007. View at: Google Scholar
  72. S. I. Moskovtsev, I. Lecker, J. B. M. Mullen et al., “Cause-specific treatment in patients with high sperm DNA damage resulted in significant DNA improvement,” Systems Biology in Reproductive Medicine, vol. 55, no. 2-3, pp. 109–115, 2009. View at: Publisher Site | Google Scholar
  73. G. J. Song, E. P. Norkus, and V. Lewis, “Relationship between seminal ascorbic acid and sperm DNA integrity in infertile men,” International Journal of Andrology, vol. 29, no. 6, pp. 569–575, 2006. View at: Publisher Site | Google Scholar

Copyright © 2012 Mona Bungum. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

3812 Views | 1461 Downloads | 33 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.